Last reviewed · How we verify
CD19-BCMA CAR-T cells infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CD19-BCMA CAR-T cells infusion (CD19-BCMA CAR-T cells infusion) — Beijing GoBroad Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD19-BCMA CAR-T cells infusion TARGET | CD19-BCMA CAR-T cells infusion | Beijing GoBroad Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD19-BCMA CAR-T cells infusion CI watch — RSS
- CD19-BCMA CAR-T cells infusion CI watch — Atom
- CD19-BCMA CAR-T cells infusion CI watch — JSON
- CD19-BCMA CAR-T cells infusion alone — RSS
Cite this brief
Drug Landscape (2026). CD19-BCMA CAR-T cells infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/cd19-bcma-car-t-cells-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab